Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (41-50 of 188) with videos related to

Pageof 19
Sort By:
Kidney International Reports|May 15, 2020
Comparison of 2 Serum-Free Light-Chain Assays in CKD PatientsBen Sprangers, Kathleen Claes, Pieter Evenepoel, et al.
Blood|February 28, 2002
Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)Jan Cools, Nicole Mentens, Maria D Odero, et al.
Blood|December 18, 2012
A novel role of BMP4 in adult hematopoietic stem and progenitor cell homing via Smad independent regulation of integrin-α4 expressionSatish Khurana, Shannon Buckley, Sarah Schouteden, et al.
Mayo Clinic Proceedings|September 2, 2009
Monoclonal gammopathy of undetermined significance: significant beyond hematologySteven Vanderschueren, Marieke Mylle, Daan Dierickx, et al.
Leukemia & Lymphoma|June 24, 2017
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasoneDan T Vogl, Michel Delforge, Kevin Song, et al.
Circulation. Cardiovascular Imaging|March 17, 2017
Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation ParametersEfstathios D Pagourelias, Oana Mirea, Jürgen Duchenne, et al.
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
Leukemia & Lymphoma|May 30, 2015
Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trialMichel Delforge, Timothy Devos, Jacob Rowe, et al.
Acta Clinica Belgica|December 23, 2020
Recommendations on the management of multiple myeloma in 2020Marie-Christiane Vekemans, Chantal Doyen, Jo Caers, et al.
BMJ Open|July 16, 2020
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart reviewRoman Hájek, Sebastian Gonzalez-McQuire, Zsolt Szabo, et al.
Pageof 19

Showing results (41-50 of 188) with videos related to

Sort By:
Pageof 19
Kidney International Reports|May 15, 2020
Comparison of 2 Serum-Free Light-Chain Assays in CKD PatientsBen Sprangers, Kathleen Claes, Pieter Evenepoel, et al.
Blood|February 28, 2002
Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)Jan Cools, Nicole Mentens, Maria D Odero, et al.
Blood|December 18, 2012
A novel role of BMP4 in adult hematopoietic stem and progenitor cell homing via Smad independent regulation of integrin-α4 expressionSatish Khurana, Shannon Buckley, Sarah Schouteden, et al.
Mayo Clinic Proceedings|September 2, 2009
Monoclonal gammopathy of undetermined significance: significant beyond hematologySteven Vanderschueren, Marieke Mylle, Daan Dierickx, et al.
Leukemia & Lymphoma|June 24, 2017
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasoneDan T Vogl, Michel Delforge, Kevin Song, et al.
Circulation. Cardiovascular Imaging|March 17, 2017
Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation ParametersEfstathios D Pagourelias, Oana Mirea, Jürgen Duchenne, et al.
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
Leukemia & Lymphoma|May 30, 2015
Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trialMichel Delforge, Timothy Devos, Jacob Rowe, et al.
Acta Clinica Belgica|December 23, 2020
Recommendations on the management of multiple myeloma in 2020Marie-Christiane Vekemans, Chantal Doyen, Jo Caers, et al.
BMJ Open|July 16, 2020
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart reviewRoman Hájek, Sebastian Gonzalez-McQuire, Zsolt Szabo, et al.
Pageof 19